Cabaletta Bio, Inc. develops engineered T cell therapies for autoimmune diseases as a late-stage clinical biotechnology company. Its CABA platform includes the CARTA strategy, and its lead investigational therapy, rese-cel (resecabtagene autoleucel), is a fully human CD19-CAR T cell therapy evaluated through the RESET clinical development program across rheumatology, neurology and dermatology.
Recurring company updates cover rese-cel clinical and translational data, trial-program presentations, manufacturing scale-up, and supply arrangements using automated cell-therapy production platforms. News also includes financial results, business updates, conference participation, shareholder voting matters, capital-structure disclosures, and regulatory disclosures tied to Cabaletta Bio’s autoimmune cell-therapy pipeline.
Cabaletta Bio, Inc. (CABA) announced promising in vivo preclinical data for its Chimeric AutoAntibody Receptor T cells targeting MuSK-associated myasthenia gravis. Presenting at AAN 2020, the data showed the T cells effectively recognized and eliminated B cells expressing anti-MuSK antibodies, with no harm to normal B cells. The study supports plans for Investigational New Drug (IND)-enabling studies in 2020, addressing a significant unmet need in MuSK MG treatment.
Cabaletta Bio, Inc. (CABA) announced its Q1 2020 financial results, highlighting a significant milestone with the FDA granting Fast Track Designation for its lead candidate, DSG3-CAART, aimed at treating mucosal pemphigus vulgaris (mPV). The Phase 1 DesCAARTes™ trial is ready to launch pending COVID-19 restrictions. R&D expenses were $4.6 million, while G&A expenses totaled $3.3 million. Cash reserves stood at $131 million, projected to support operations through Q3 2022.